Alternately, SERT inhibitors might worsen Parkinsonism via a 5-HT-mediated activation of presynaptic 5-HT1A receptors [127], which would result in less dopamine being released from raphe-striatal terminals. Here, SLC6A4 is linked to Parkinson disease.